Assessing Tenapanor as a Treatment of CF-related Constipation.
Assessing Tenapanor as a Treatment of CF-related Constipation.
Active, not recruiting · NCT06810167 · Registry updated 2026-08-21Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Assessing Tenapanor as a Treatment of CF-related Constipation. | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Digestive System Diseases, Infant, Newborn, Diseases, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Signs and Symptoms, Digestive, constipation disorder, cystic fibrosis, hereditary disease, lung disorder, pancreas disorder, respiratory system disorder | Active, not recruiting | Phase 3 | 2026-08-21 | NCT06810167 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Ardelyx | 4 |
| Massachusetts General Hospital | 758 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Massachusetts General Hospital | Boston | United States | 1015 |